ReviewThe Journal of antibiotics2018
Kanamycin and its derivative, arbekacin: significance and impact.
Review in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 40 citations in OpenAlex.
- Design and Characterization of Aptamers to Antibiotic Kanamycin with Improved Affinity.International journal of molecular sciences · 2025Article
- Structure-function comparison of Arbekacin with other aminoglycosides elucidates its higher potency as bacterial translation inhibitor.Scientific reports · 2025Article
- Biomimetic culture substrates for modelling homeostatic intestinal epithelium in vitro.Nature communications · 2025Article
- Innovative aspects and applications of single cell technology for different diseases.American journal of cancer research · 2024Review
- Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Effects of thiram exposure on liver metabolism of chickens.Frontiers in veterinary science · 2023Article
- Basic and applied research on multiple aminoglycoside antibiotic resistance of actinomycetes: an old-timer's recollection.Journal of industrial microbiology & biotechnology · 2021Article
- Mechanistic insights into translation inhibition by aminoglycoside antibiotic arbekacin.Nucleic acids research · 2021Article
- Pyridoxal-5'-phosphate-dependent enzyme GenB3 Catalyzes C-3',4'-dideoxygenation in gentamicin biosynthesis.Microbial cell factories · 2021Article
- A Novel Method for Antibiotic Detection in Milk Based on Competitive Magnetic Immunodetection.Foods (Basel, Switzerland) · 2020Article
- Synthesis of Ring II/III Fragment of Kanamycin: A New Minimum Structural Motif for Aminoglycoside Recognition.Antibiotics (Basel, Switzerland) · 2019Article
- Plasticity of Aminoglycoside Binding to Antibiotic Kinase APH(2″)-Ia.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On the occasion of the 60th anniversary of the discovery (1957) of kanamycin (KM), a series of research achievements on KM and its semisynthetic derivative Arbekacin (ABK) are outlined. KM was first used clinically in 1958 and was appreciated for its remarkable curing effect on various bacterial infections, especially tuberculosis. ABK is a KM derivative rationally semisynthesized to overcome KM resistance due to enzymatic phosphorylation and acetylation. Since its approval in 1990 as an anti-MRSA drug, ABK has been and still is effectively used in chemotherapy because MRSA rarely develops high ABK-resistance. Research that illuminated the unique features of ABK enabling it to resist the development of resistance by MRSA are also described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.